Eligibility for Semaglutide 2.4 mg in US Adults with Obesity and Prediabetes, Based on the STEP-10 Trial Criteria

被引：0
|
作者：
Chetty, Ashwin K.
Khunte, Mihir
Lu, Yuan
Chen, Alissa S.
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Brown Univ, Warren Alpert Med Sch, Providence, RI USA
[3] Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[4] Yale Sch Med, Dept Internal Med, Natl Clinician Scholars Program, New Haven, CT USA
来源：
AMERICAN HEART JOURNAL | 2024年 / 278卷
关键词：
obesity; prediabetes; semaglutide;
D O I：
10.1016/j.ahj.2024.09.026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0057
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
    Garvey, W. Timothy
    Hesse, Dan
    Joseph, Frank
    Koroleva, Anna
    Kushner, Robert F.
    le Roux, Carel W.
    Lim, Soo
    Lingvay, Ildiko
    Mosenzon, Ofri
    Wallenstein, Signe O. R.
    Wadden, Thomas A.
    OBESITY SURGERY, 2021, 31 (SUPPL 1) : S11 - S11
  • [32] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
    W. Timothy Garvey
    Rachel L. Batterham
    Meena Bhatta
    Silvio Buscemi
    Louise N. Christensen
    Juan P. Frias
    Esteban Jódar
    Kristian Kandler
    Georgia Rigas
    Thomas A. Wadden
    Sean Wharton
    Nature Medicine, 2022, 28 : 2083 - 2091
  • [33] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
    Garvey, W. Timothy
    Batterham, Rachel L.
    Bhatta, Meena
    Buscemi, Silvio
    Christensen, Louise N.
    Frias, Juan P.
    Jodar, Esteban
    Kandler, Kristian
    Rigas, Georgia
    Wadden, Thomas A.
    Wharton, Sean
    NATURE MEDICINE, 2022, 28 (10) : 2083 - +
  • [34] Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
    Perreault, Leigh
    Davies, Melanie
    Frias, Juan P.
    Laursen, Peter Norkjaer
    Lingvay, Ildiko
    Machineni, Sriram
    Varbo, Anette
    Wilding, John P. H.
    Wallenstein, Signe Olrik Rytter
    le Roux, Carel W.
    DIABETES CARE, 2022, 45 (10) : 2396 - 2405
  • [35] Improvement in insulin sensitivity and glucose metabolism in adolescents with obesity treated with once-weekly semaglutide 2.4 mg: a secondary analysis of the STEP TEENS trial
    Arslanian, Silva
    Goldman, Bryan
    Gies, Inge
    Harder-Lauridsen, Nina M.
    Karlsson, Tobias
    Kelly, Aaron
    Wabitsch, Martin
    Weghuber, Daniel
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 : 76 - 76
  • [36] CONTINUED TREATMENT WITH SEMAGLUTIDE 2.4 MG LEADS TO SUSTAINED IMPROVEMENTS IN CARDIOMETABOLIC RISK FACTORS IN THE STEP 4 TRIAL
    Verma, Subodh
    Bhatta, Meena
    Davies, Melanie
    Deanfield, John
    Garvey, Tim
    Jensen, Camilla
    Khalid, Usman
    Kushner, Robert
    Rubino, Domenica M.
    Kosiborod, Mikhail
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1608 - 1608
  • [37] Continued Semaglutide 2.4 mg Once Weekly Improved Health Related Quality of Life in the STEP 4 Trial
    Sharma, Arya
    Meincke, Henrik
    Jensen, Camilla
    Kushner, Robert
    Pedersen, Sue
    Rubino, Domenica
    Tran, Marie
    Wharton, Sean
    Bjorner, Jakob
    OBESITY, 2021, 29 : 9 - 10
  • [38] Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
    Davies, Melanie
    Faerch, Louise
    Jeppesen, Ole K.
    Pakseresht, Arash
    Pedersen, Sue D.
    Perreault, Leigh
    Rosenstock, Julio
    Shimomura, Iichiro
    Viljoen, Adie
    Wadden, Thomas A.
    Lingvay, Ildiko
    LANCET, 2021, 397 (10278): : 971 - 984
  • [39] Associations between weight loss and glycaemic control with once-weekly semaglutide 1.0 mg and 2.4 mg in the STEP 2 trial
    Davies, M.
    Faerch, L.
    Goldman, B.
    Pakseresht, A.
    Pedersen, S.
    Rosenstock, J.
    Lingvay, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S254 - S255
  • [40] The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
    Friedrichsen, Martin
    Breitschaft, Astrid
    Tadayon, Sayeh
    Wizert, Alicja
    Skovgaard, Dorthe
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 754 - 762
12345